Advertisement

Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations

  • Linda Björkhem-Bergman
  • Eva Andersén-Karlsson
  • Richard Laing
  • Eduardo Diogene
  • Oyvind Melien
  • Malena Jirlow
  • Rickard E. Malmström
  • Sabine Vogler
  • Brian Godman
  • Lars L Gustafsson
Special Article

Abstract

Purpose

In September 2012 an interactive course on the “Interface Management of Pharmacotherapy” was organized by the Stockholm Drug and Therapeutics Committee in cooperation with Department of Clinical Pharmacology at Karolinska Institutet and at Karolinska University Hospital in Stockholm, Sweden, in collaboration with the WHO. The basis for the course was the “Stockholm model” for the rational use of medicines but also contained presentations about successful models in interface management of pharmacotherapy in other European countries.

Methods

The “Stockholm model” consists of 8 components: 1) Independent Drug and Therapeutics Committee with key role for respected drug experts with policy for “interest of conflicts”, 2) The “Wise List”, recommendations of medicines jointly for primary and hospital care, 3) Communication strategy with continuous medical education, 4) Systematic introduction of new expensive medicines, 5) E-pharmacological support at “point of care”, 6) Methods and tools for follow-up of medicines use, 7) Medicines policy strategy and 8) Operative resources.

Results

The course highlighted the importance of efficient and targeted communication of drug recommendations building on trust among prescribers and patients for the guidelines to achieve high adherence. Trust is achieved by independent Drug and Therapeutics Committees with a key role for respected experts and a strict policy for “conflicts of interest”. Representations of GPs are also crucial for successful implementation, being the link between evidence based medicine and practice.

Conclusion

The successful models in Scotland and in Stockholm as well as the ongoing work in Catalonia were considered as examples of multifaceted approaches to improve the quality of medicine use across primary and hospital care.

Keywords

Interface management Rational use of medicines Drug committees Pharmacoeconomics 

Notes

Acknowledgments

This work was in part supported by grants from the Karolinska Institutet, Sweden. No writing assistance was provided for this paper.

Financial disclosure

There are no conflicts of interest reported by any of the authors. However, Eva Andersén-Karlsson is chairman of the DTC in Stockholm County Council.

References

  1. 1.
    Diogene E, Figueras A (2011) What public policies have been more effective in promoting rational prescription of drugs? J Epidemiol Community Health 65(5):387–388PubMedCrossRefGoogle Scholar
  2. 2.
    Laing R, Waning B, Gray A, Ford N (2003) E. t Hoen, 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361(9370):1723–1729PubMedCrossRefGoogle Scholar
  3. 3.
    Gustafsson LL, Wettermark B, Godman B, Andersen-Karlsson E, Bergman U, Hasselstrom J et al (2011) The ‘wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 108(4):224–233PubMedCrossRefGoogle Scholar
  4. 4.
    Midlov P, Bergkvist A, Bondesson A, Eriksson T, Hoglund P (2005) Medication errors when transferring elderly patients between primary health care and hospital care. Pharm World Sci 27(2):116–120PubMedCrossRefGoogle Scholar
  5. 5.
    Coma A, Zara C, Godman B, Agusti A, Diogene E, Wettermark B et al (2009) Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev Pharmacoecon Outcomes Res 9(6):569–581PubMedCrossRefGoogle Scholar
  6. 6.
    Dear J, O’Dowd C, Timoney A, Paterson KR, Walker A, Webb DJ (2007) Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland. Scott Med J 52(3):20–26PubMedCrossRefGoogle Scholar
  7. 7.
    Laing R, Ruredzo R (1989) The essential drugs programme in Zimbabwe: new approaches to training. Health Policy Plan 4(3):229–234CrossRefGoogle Scholar
  8. 8.
    Laing R (1991) Essential drugs programmes in Africa. Afr Health 14(1):32–33PubMedGoogle Scholar
  9. 9.
    Forløpsgruppe “Riktig legemiddelbruk (2009) Oslo, Norway. http://www.regjeringen.no/upload/HOD/Dokumenter%20SAM/Forl%C3%B8psrapporter/Forl%C3%B8psgruppe%206%20-%20Riktig%20legemiddelbruk.pdf Date of access: Feb 12th 2013
  10. 10.
    En helhetlig integreringspolitikk. Mangfold og fellesskap (2012–2013) Melding til Stortinget: Oslo, Norway. http://www.regjeringen.no/nb/dep/hod/dok/regpubl/stmeld/2010-2011/meld-st-16-20102011/8/6.html?id=639843. Date of acess: Feb 12th 2013
  11. 11.
    Spinewine A, Foulon V, Claeys C, Lepeleire JD, Chevalier P, Desplenter F (2010) Seamless care focusing on medication between hospital and home. Belgian Health Care Knowledge Centre (KCE), BrusselsGoogle Scholar
  12. 12.
    Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N (2010) PHIS hospital pharma report. Pharmaceutical Health Information System (PHIS), ViennaGoogle Scholar
  13. 13.
    Grol R, Grimshaw J (2003) From best evidence to best practice: effective implementation of change in patients’ care. Lancet 362(9391):1225–1230PubMedCrossRefGoogle Scholar
  14. 14.
    Sjöqvist F, Bergman U, Dahl ML, Gustafsson LL, Hensjö LO (2002) Drug and therapeutics committees: a Swedish experience. Drug Inf 12:207–213, WHOGoogle Scholar
  15. 15.
    Godman B,Gustafsson LL (2013) A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Correspondence. Appl Health Econ Health Policy 11:79–82Google Scholar
  16. 16.
    Persson U, Svensson J, Pettersson B (2012) A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 10(4):217–225PubMedCrossRefGoogle Scholar
  17. 17.
    Abernethy D, Birkett D, Brosen DK, Cascorbi I, Gustafsson LL, Hoppu K et al (2012) Clinical pharmacology in health care, teaching and research. Joint publication by WHO, CIOMS and IUPHAR (International Union of Pharmacology and Clinical Pharmacology). WHO, Geneva. Available at: http://www.cioms.ch/index.php/component/booklibrary/?task=view&Itemid=&id=46&catid=58
  18. 18.
    Godman B, Paterson K, Malmstrom RE, Selke G, Fagot JP, Mrak J (2012) Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 12(4):439–441PubMedCrossRefGoogle Scholar
  19. 19.
    Holmstrom M, Johnsson H, Larfars G, Malmstrom R, Hjemdahl P (2009) New drug in atrial fibrillation—how does it function in regular health care? Lakartidningen 106(45):3019–3020PubMedGoogle Scholar
  20. 20.
    Covvey JR, McTaggart S, Bishop I (2010) Management of medication use in Scotland. Am J Health Syst Pharm 67(16):1378–1382PubMedCrossRefGoogle Scholar
  21. 21.
    Bottiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjo ML et al (2009) SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65(6):627–633PubMedCrossRefGoogle Scholar
  22. 22.
    Sjoborg B, Backstrom T, Arvidsson LB, Andersen-Karlsson E, Blomberg LB, Eiermann B et al (2007) Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region–Bridging the gap between knowledge and practice. Int J Med Inform 76(7):497–506PubMedCrossRefGoogle Scholar
  23. 23.
    Kotler P (2000) Marketing management, 10th edn. ed. New Jersey: Upper Saddle RiverGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Linda Björkhem-Bergman
    • 1
    • 10
  • Eva Andersén-Karlsson
    • 2
  • Richard Laing
    • 3
  • Eduardo Diogene
    • 4
  • Oyvind Melien
    • 5
  • Malena Jirlow
    • 6
  • Rickard E. Malmström
    • 7
  • Sabine Vogler
    • 8
  • Brian Godman
    • 1
    • 9
  • Lars L Gustafsson
    • 1
  1. 1.Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska InstitutetKarolinska University Hospital HuddingeStockholmSweden
  2. 2.Drug and Therapeutics Committee, Unit of Medicine Support, Public Healthcare Services, Stockholm County Council and Department of Clinical Science and EducationKarolinska Institutet SödersjukhusetStockholmSweden
  3. 3.Department of Essential Medicines and Health ProductsWHO GenevaGenevaSwitzerland
  4. 4.Unit of Medicines Coordination and Strategy, Department of Health Care AffairsCatalan Institute of HealthBarcelonaSpain
  5. 5.Department of Medical Devices and Medicinal ProductsNorwegian Directorate of HealthOsloNorway
  6. 6.Unit of Medicine Support, Public Healthcare ServicesStockholm County CouncilStockholmSweden
  7. 7.Division of Clinical Pharmacology, Department of Medicine, Karolinska InstitutetKarolinska University Hospital SolnaStockholmSweden
  8. 8.WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Health EconomicsGesundheit Österreich GmbH (Austrian Health Institute)ViennaAustria
  9. 9.Strathclyde Institute of Pharmacy and Biomedical SciencesUniversity of StrathclydeGlasgowUK
  10. 10.Division of Clinical Pharmacology C1-68Karolinska University Hospital, Huddinge, Karolinska InstitutetStockholmSweden

Personalised recommendations